Black Diamond co-founders David Epstein (L) and Elizabeth Buck
April 25, 2022 10:22 AM EDT
People
R&D

Black Di­a­mond lays off 30% of its work­force and culls a drug from its 'Mas­terKey' chest

Kyle LaHucik

Senior Reporter

With every round of lay­offs, the dol­drums of the biotech bear mar­ket get ever dark­er and more de­press­ing. Black Di­a­mond Ther­a­peu­tics is the lat­est to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times